Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development and pharmacokinetic characterization of pulmonal and intravenous delta‐9‐tetrahydrocannabinol (THC) in humans

Development and pharmacokinetic characterization of pulmonal and intravenous... The aim of the present study was to develop a physiologically compatible inhalation solution of delta‐9‐tetrahydrocannabinol (THC), and to compare the pharmacokinetic and analgesic properties of pulmonal THC versus pulmonal placebo and intravenous (iv) THC, respectively. Eight healthy volunteers were included in this randomized, double‐blind, crossover study. The aqueous THC formulations were prepared by using a solubilization technique. iv THC (0.053 mg/kg body weight), pulmonal THC (0.053 mg/kg), or a placebo inhalation solution was administered as single dose. At defined time points, blood samples were collected, and somatic and psychotropic side effects as well as vital functions monitored. An ice water immersion test was performed to measure analgesia. Using a pressure‐driven nebulizer, the pulmonal administration of the THC liquid aerosol resulted in high THC peak plasma levels within minutes. The bioavailability of the pulmonal THC was 28.7 ± 8.2% (mean ± SEM). The side effects observed after pulmonal THC were coughing and slight irritation of the upper respiratory tract, very mild psychotropic symptoms, and headache. The side effects after iv THC were much more prominent. Neither pulmonal nor iv THC significantly reduced experimentally induced pain. © 2004 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1176–1184, 2004 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Pharmaceutical Sciences Wiley

Development and pharmacokinetic characterization of pulmonal and intravenous delta‐9‐tetrahydrocannabinol (THC) in humans

Loading next page...
 
/lp/wiley/development-and-pharmacokinetic-characterization-of-pulmonal-and-PYxCxBX0ST
Publisher
Wiley
Copyright
Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0022-3549
eISSN
1520-6017
DOI
10.1002/jps.20037
pmid
15067694
Publisher site
See Article on Publisher Site

Abstract

The aim of the present study was to develop a physiologically compatible inhalation solution of delta‐9‐tetrahydrocannabinol (THC), and to compare the pharmacokinetic and analgesic properties of pulmonal THC versus pulmonal placebo and intravenous (iv) THC, respectively. Eight healthy volunteers were included in this randomized, double‐blind, crossover study. The aqueous THC formulations were prepared by using a solubilization technique. iv THC (0.053 mg/kg body weight), pulmonal THC (0.053 mg/kg), or a placebo inhalation solution was administered as single dose. At defined time points, blood samples were collected, and somatic and psychotropic side effects as well as vital functions monitored. An ice water immersion test was performed to measure analgesia. Using a pressure‐driven nebulizer, the pulmonal administration of the THC liquid aerosol resulted in high THC peak plasma levels within minutes. The bioavailability of the pulmonal THC was 28.7 ± 8.2% (mean ± SEM). The side effects observed after pulmonal THC were coughing and slight irritation of the upper respiratory tract, very mild psychotropic symptoms, and headache. The side effects after iv THC were much more prominent. Neither pulmonal nor iv THC significantly reduced experimentally induced pain. © 2004 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1176–1184, 2004

Journal

Journal of Pharmaceutical SciencesWiley

Published: May 1, 2004

Keywords: ; ; ; ;

References